Biotransformation of Silybin and its Congeners

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33146000" target="_blank" >RIV/61989592:15110/13:33146000 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61388971:_____/13:00423434

Výsledek na webu

<a href="http://www.eurekaselect.com/118087/article" target="_blank" >http://www.eurekaselect.com/118087/article</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1389200214666131118234507" target="_blank" >10.2174/1389200214666131118234507</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biotransformation of Silybin and its Congeners

Popis výsledku v původním jazyce

Silybin and its congeners belong to a group of flavonolignans with strong biological activities. These compounds are potentially applicable in human medicine, e. g. due to their cytoprotective activity. As a part of herbal preparations available on the open market, they face the risk of potential negative drug-drug interactions. This review aims to evaluate current knowledge on the metabolism of these compounds by biotransformation enzymes, interactions with other drugs, their pharmacokinetics, and bioavailability. While silybin and its derivatives interact with cytochrome P450s, only metabolism of silybin by cytochrome P450 2C8 poses a risk of adverse effects. The main biotransformation route of silybin and derivatives was identified as conjugation, which is sterospecific in case of silybin. Studies of the metabolism, pharmacokinetics, potentional drug - drug interactions 26 and increasing bioavailability of these flavonolignans play an important facet of possible therapeutical use of

Název v anglickém jazyce

Biotransformation of Silybin and its Congeners

Popis výsledku anglicky

Silybin and its congeners belong to a group of flavonolignans with strong biological activities. These compounds are potentially applicable in human medicine, e. g. due to their cytoprotective activity. As a part of herbal preparations available on the open market, they face the risk of potential negative drug-drug interactions. This review aims to evaluate current knowledge on the metabolism of these compounds by biotransformation enzymes, interactions with other drugs, their pharmacokinetics, and bioavailability. While silybin and its derivatives interact with cytochrome P450s, only metabolism of silybin by cytochrome P450 2C8 poses a risk of adverse effects. The main biotransformation route of silybin and derivatives was identified as conjugation, which is sterospecific in case of silybin. Studies of the metabolism, pharmacokinetics, potentional drug - drug interactions 26 and increasing bioavailability of these flavonolignans play an important facet of possible therapeutical use of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Drug Metabolism

ISSN

1389-2002

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

13

Strana od-do

1009-1021

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—